Trial Profile
A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2021
Price :
$35
*
At a glance
- Drugs Mipicoledine (Primary)
- Indications Brain cancer; Brain metastases; Breast cancer; Lung cancer; Malignant melanoma
- Focus Therapeutic Use
- Sponsors Dekk-Tec
- 10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research
- 05 Apr 2017 Results (n=53) from this and one more study (NCT01048008) presented at the 108th Annual Meeting of the American Association for Cancer Research.
- 05 Apr 2017 Results of this and other trial (see CTP 700052826) presented at the 108th Annual Meeting of the American Association for Cancer Research